Navigation Links
Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
Date:1/9/2014

risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate partners for development, commercial manufacturing and marketing and sales activities for the Company's partnered programs; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2012 and on Form 10-Q for the quarter ended September 30, 2013. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
2. Neurocrine Biosciences Reports First Quarter 2012 Results
3. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
5. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
7. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
8. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
11. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... and HAMPTON, N.J. , March 5, ... MNK ), a leading global specialty biopharmaceutical company, ... today that they have entered into a definitive agreement ... Inc. from a Madison Dearborn -led investor group ... Subject to customary closing conditions, the parties ...
(Date:3/5/2015)... 05, 2015 Research and Markets ( ... "Global Rising Stars Outlook 2015" report to their ... are being sought after with fresh vigor as new ... which is poised to bring a paradigm change in ... is the Stem cell therapy/Regenerative Medicine space. ...
(Date:3/5/2015)... -- According to a new market research ... Disposables), by Type (Invasive, Minimally Invasive, Non-Invasive), by End-User ... - Analysis & Global Forecast to 2019" , the ... $1,107.4 Million by 2019 from $887.8 Million in 2014, ... 4.5% during the forecast period. Browse ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 2Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 5Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 6Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 7Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 8Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 9Global Pharma Rising Stars Outlook 2015 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 3Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 4
... ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... STEWARTVILLE, Minn., Oct. 25 Rochester Medical Corporation (Nasdaq: ... close on Thursday, November 4, 2010.  The Company will then ...  The call will begin at 3:30 p.m. central time (4:30 ... by Thomson/CCBN and can be accessed at Rochester Medical,s website ...
Cached Medicine Technology:Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 2Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 3Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 4Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 5Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 6Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 7Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 8Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 9Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 10Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis 11Rochester Medical Announces Fourth Quarter 2010 Earnings Conference Call Thursday, November 4, 2010 2
(Date:3/5/2015)... 2015 Shania Twain will be touring ... decade. She has hinted that this will be her final ... perform one last time. She has had a residency in ... sweetheart has millions of loyal fans around the world. After ... Canada, and on June 30th she will be at Madison Square ...
(Date:3/5/2015)... York, New York (PRWEB) March 05, 2015 ... of men who allegedly suffered heart attacks, strokes and ... prescription low testosterone therapies continue to move forward in ... Court, Northern District of Illinois. According to a Case ... set forth procedures for the use of master pleadings ...
(Date:3/5/2015)... Los Angeles, CA (PRWEB) March 05, 2015 ... online article titled “Butt Augmentation, Labiaplasty on the Rise, ... surveys reported by the American Society for Aesthetic ... Plastic Surgeons . Both groups reported a year-over-year doubling ... one of the physicians quoted in the article, this ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... in healthcare communications and education, announced today its ... (AMP), the nation’s only medical conference designed for ... ischemia and lower limb amputation due to vascular ... family of innovative, evidence-based publications and CME activities ...
(Date:3/5/2015)... Venice, FL (PRWEB) March 05, 2015 ... their 15th annual listing of “Pros to Know” in ... announce that two members of MEBC’s leadership team were ... Rhodes were nominated and received this award due to ... use of innovative methods for meeting and resolving client ...
Breaking Medicine News(10 mins):Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 2Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2
... Glenn Hackbarth (MedPAC) and Bruce Bradley (General,Motors) - ... 1 The ABIM Foundation,will dedicate its efforts ... concepts,of medical professionalism and accountability in health care ... In addition, the Foundation announced that officers of ...
... Care Advantage, JACKSONVILLE, Fla., July 1 ... home,health care agency with 11 years experience in ... in revenue. Home Care Advantage is the largest ... the largest,rehabilitation provider in Jacksonville, with its 143-bed ...
... -- The first batch of imported food,( ... for the Olympic Games has arrived. The 24.269 ... in Shanghai on June 18. To ensure the,smooth ... Quarantine Bureau,took great care in their preparations prior ...
... 20% of persons aged over 55 use colonoscopies for ... insurance funds have covered the costs since 2002. This ... Database published in the current edition of Deutsches ... , http://www.aerzteblatt.de/v4/archiv/pdf.asp?id=60551 , The authors evaluated ...
... What began as a college course project to design ... their kind, designed as therapy for children with cerebral ... affects the development of the brain and the motor ... occupational therapy have been shown to be effective treatments ...
... junk food had higher cholesterol, blood fats into adulthood, ... -- Eating an unhealthy diet during pregnancy may raise ... and blood sugar levels, British researchers report. , In ... one group of females a diet of processed junk ...
Cached Medicine News:Health News:ABIM Foundation Announces New Focus and Governance 2Health News:ABIM Foundation Announces New Focus and Governance 3Health News:Jacksonville's Largest Rehab Provider Acquires Largest Home Health Agency 2Health News:China Improves Safety Management on Imported Foods in Preparation for Olympic Games 2Health News:Toys and technology for rehabilitation in cerebral palsy patients 2Health News:Toys and technology for rehabilitation in cerebral palsy patients 3Health News:Mom's Unhealthy Diet May Have Long-Term Impact on Baby 2
... Cortisol Range Verifiers have been validated for ... Immunodiagnostic Products Cortisol Reagent Pack and Vitros,Immunodiagnostic ... low and,high cortisol concentrations, close to the ... be used,to verify measurement of cortisol at ...
Rapid assay, results in 1 hours,Range 20-800 ng/mL; sensitivity 2.5 ng/mL,Can be used for animal sera; requires extraction protocol and steroid free serum...
... 1000 assays are designed for ... IMMULITE 1000, continuous random access ... in both design and operation. ... in a wide variety of ...
... XCAT 100 X-Ray System from KUBTEC is a ... two and three dimensional representation of the specimen ... reconstruction of specimen X-ray images, the micro focus ... level of detail in standard 2D images. The ...
Medicine Products: